Cytek Biosciences Analyst Ratings
Cytek Biosciences Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
10/16/2023 | 95.89% | Piper Sandler | $15 → $10 | Maintains | Overweight |
07/19/2023 | — | Raymond James | Initiates Coverage On | → Market Perform | |
05/11/2023 | 154.65% | Morgan Stanley | $14 → $13 | Maintains | Equal-Weight |
05/10/2023 | 135.06% | Goldman Sachs | $14 → $12 | Maintains | Buy |
03/07/2023 | 193.83% | Piper Sandler | $18 → $15 | Maintains | Overweight |
03/02/2023 | 174.24% | Morgan Stanley | $15 → $14 | Maintains | Equal-Weight |
03/02/2023 | 174.24% | Goldman Sachs | $16 → $14 | Maintains | Buy |
08/18/2022 | 213.42% | Piper Sandler | $12 → $16 | Maintains | Overweight |
08/12/2022 | 193.83% | Morgan Stanley | $11 → $15 | Maintains | Equal-Weight |
08/11/2022 | 233.01% | Goldman Sachs | $15 → $17 | Maintains | Buy |
07/14/2022 | 193.83% | Goldman Sachs | $12 → $15 | Maintains | Buy |
05/16/2022 | 135.06% | Piper Sandler | $17 → $12 | Maintains | Overweight |
05/13/2022 | 115.48% | Morgan Stanley | $18 → $11 | Maintains | Equal-Weight |
05/12/2022 | 135.06% | Goldman Sachs | $14 → $12 | Maintains | Buy |
04/13/2022 | 174.24% | Goldman Sachs | $28 → $14 | Maintains | Buy |
02/15/2022 | 252.6% | Morgan Stanley | $27 → $18 | Maintains | Equal-Weight |
08/17/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
08/17/2021 | 409.3% | Morgan Stanley | → $26 | Initiates Coverage On | → Equal-Weight |
08/17/2021 | 448.48% | Goldman Sachs | → $28 | Initiates Coverage On | → Buy |
08/17/2021 | 448.48% | Piper Sandler | → $28 | Initiates Coverage On | → Overweight |
日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
---|---|---|---|---|---|
2023 年 10 月 16 日 | 95.89% | 派珀·桑德勒 | 15 美元 → 10 美元 | 維護 | 超重 |
07/19/2023 | — | 雷蒙德·詹姆 | 啓動覆蓋範圍開啓 | → 市場表現 | |
05/11/2023 | 154.65% | 摩根士丹利 | 14 美元 → 13 美元 | 維護 | 重量相等 |
05/10/2023 | 135.06% | 高盛 | 14 美元 → 12 美元 | 維護 | 買 |
03/07/2023 | 193.83% | 派珀·桑德勒 | 18 美元 → 15 美元 | 維護 | 超重 |
03/02/2023 | 174.24% | 摩根士丹利 | 15 美元 → 14 美元 | 維護 | 重量相等 |
03/02/2023 | 174.24% | 高盛 | 16 美元 → 14 美元 | 維護 | 買 |
08/18/2022 | 213.42% | 派珀·桑德勒 | 12 美元 → 16 美元 | 維護 | 超重 |
2022 年 12 月 8 日 | 193.83% | 摩根士丹利 | 11 美元 → 15 美元 | 維護 | 重量相等 |
08/11/2022 | 233.01% | 高盛 | 15 美元 → 17 美元 | 維護 | 買 |
07/14/2022 | 193.83% | 高盛 | 12 美元 → 15 美元 | 維護 | 買 |
05/16/2022 | 135.06% | 派珀·桑德勒 | 17 美元 → 12 美元 | 維護 | 超重 |
05/13/2022 | 115.48% | 摩根士丹利 | 18 美元 → 11 美元 | 維護 | 重量相等 |
05/12/2022 | 135.06% | 高盛 | 14 美元 → 12 美元 | 維護 | 買 |
2022 年 4 月 13 日 | 174.24% | 高盛 | 28 美元 → 14 美元 | 維護 | 買 |
2022 年 2 月 15 日 | 252.6% | 摩根士丹利 | 27 美元 → 18 美元 | 維護 | 重量相等 |
2021 年 8 月 17 日 | — | Cowen & Co. | 啓動覆蓋範圍開啓 | → 跑贏大盤 | |
2021 年 8 月 17 日 | 409.3% | 摩根士丹利 | → 26 美元 | 啓動覆蓋範圍開啓 | → 重量相等 |
2021 年 8 月 17 日 | 448.48% | 高盛 | → 28 美元 | 啓動覆蓋範圍開啓 | → 購買 |
2021 年 8 月 17 日 | 448.48% | 派珀·桑德勒 | → 28 美元 | 啓動覆蓋範圍開啓 | → 超重 |
What is the target price for Cytek Biosciences (CTKB)?
Cytek Biosciences(CTKB)的目標價格是多少?
The latest price target for Cytek Biosciences (NASDAQ: CTKB) was reported by Piper Sandler on October 16, 2023. The analyst firm set a price target for $10.00 expecting CTKB to rise to within 12 months (a possible 95.89% upside). 7 analyst firms have reported ratings in the last year.
派珀·桑德勒於2023年10月16日公佈了Cytek Biosciences(納斯達克股票代碼:CTKB)的最新目標股價。該分析公司將目標股價定爲10.00美元,預計CTKB將在12個月內上漲至95.89%(可能上漲95.89%)。去年有7家分析公司公佈了評級。
What is the most recent analyst rating for Cytek Biosciences (CTKB)?
Cytek Biosciences(CTKB)的最新分析師評級是多少?
The latest analyst rating for Cytek Biosciences (NASDAQ: CTKB) was provided by Piper Sandler, and Cytek Biosciences maintained their overweight rating.
派珀·桑德勒提供了Cytek Biosciences(納斯達克股票代碼:CTKB)的最新分析師評級,Cytek Biosciences維持增持評級。
When is the next analyst rating going to be posted or updated for Cytek Biosciences (CTKB)?
Cytek Biosciences(CTKB)的下一個分析師評級何時公佈或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cytek Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cytek Biosciences was filed on October 16, 2023 so you should expect the next rating to be made available sometime around October 16, 2024.
分析師在進行了廣泛的研究後得出了股票評級,包括閱讀公開財務報表、與Cytek Biosciences的高管和客戶交談以及聽取業績電話會議。大多數分析師每三個月進行一次評級,因此每家公司每年應獲得4個評級。Cytek Biosciences的最後一次評級是在2023年10月16日提交的,因此你應該預計下一個評級將在2024年10月16日左右公佈。
Is the Analyst Rating Cytek Biosciences (CTKB) correct?
分析師對 Cytek Biosciences (CTKB) 的評級正確嗎?
While ratings are subjective and will change, the latest Cytek Biosciences (CTKB) rating was a maintained with a price target of $15.00 to $10.00. The current price Cytek Biosciences (CTKB) is trading at is $5.11, which is out of the analyst's predicted range.
儘管評級是主觀的,並且會發生變化,但最新的Cytek Biosciences(CTKB)評級保持不變,目標股價爲15.00美元至10.00美元。Cytek Biosciences(CTKB)目前的交易價格爲5.11美元,超出了分析師的預測區間。
譯文內容由第三人軟體翻譯。